- Home
- FUFU vs AVDL Comparison
FUFU vs AVDL Comparison
Compare FUFU & AVDL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FUFU
- AVDL
- Stock Information
- Founded
- FUFU 2020
- AVDL 2015
- Country
- FUFU Singapore
- AVDL Ireland
- Employees
- FUFU N/A
- AVDL N/A
- Industry
- FUFU
- AVDL Biotechnology: Pharmaceutical Preparations
- Sector
- FUFU
- AVDL Health Care
- Exchange
- FUFU NYSE
- AVDL Nasdaq
- Market Cap
- FUFU 871.5M
- AVDL 867.3M
- IPO Year
- FUFU N/A
- AVDL 1996
- Fundamental
- Price
- FUFU $5.35
- AVDL $8.41
- Analyst Decision
- FUFU Strong Buy
- AVDL Strong Buy
- Analyst Count
- FUFU 1
- AVDL 7
- Target Price
- FUFU $7.00
- AVDL $18.86
- AVG Volume (30 Days)
- FUFU 159.8K
- AVDL 1.3M
- Earning Date
- FUFU 03-04-2025
- AVDL 03-03-2025
- Dividend Yield
- FUFU N/A
- AVDL N/A
- EPS Growth
- FUFU 1042.93
- AVDL N/A
- EPS
- FUFU 0.23
- AVDL N/A
- Revenue
- FUFU $452,743,012.00
- AVDL $138,160,000.00
- Revenue This Year
- FUFU $66.38
- AVDL $515.49
- Revenue Next Year
- FUFU $5.25
- AVDL $48.85
- P/E Ratio
- FUFU $22.79
- AVDL N/A
- Revenue Growth
- FUFU 78.43
- AVDL 1523.50
- 52 Week Low
- FUFU $2.32
- AVDL $7.39
- 52 Week High
- FUFU $18.32
- AVDL $19.09
- Technical
- Relative Strength Index (RSI)
- FUFU 57.70
- AVDL 45.85
- Support Level
- FUFU $4.61
- AVDL $8.27
- Resistance Level
- FUFU $5.15
- AVDL $9.34
- Average True Range (ATR)
- FUFU 0.33
- AVDL 0.44
- MACD
- FUFU 0.02
- AVDL 0.09
- Stochastic Oscillator
- FUFU 88.11
- AVDL 43.29
About FUFU BITFUFU INC
BitFuFu Inc is a digital asset mining and cloud-mining service provider that fosters a secure, compliant, and transparent blockchain infrastructure. It provides stable and intelligent digital asset mining solutions, including one-stop cloud-mining services and miner hosting services to institutional customers and individual digital assets.
About AVDL Avadel Pharmaceuticals plc
Avadel Pharmaceuticals PLC is a specialty pharmaceutical company. It identifies, develops, and commercializes branded pharmaceutical products including controlled-release therapeutic products based on its proprietary drug delivery technologies in the United States. The company is engaged in development of differentiated drug products for administration in various forms such as capsules, tablets, injectables etc. Its commercialized product LUMRYZ is an extended-release formulation of sodium oxybate indicated to be taken once at bedtime for the treatment of cataplexy or EDS in adults with narcolepsy.